News

WHIM syndrome is a primary immunodeficiency disease caused by a mutation in the C-X-C receptor type 4 (CXCR4) gene, which results in susceptibility to certain types of infections. The

Celltrion submitted its abbreviated Biologics License Applications (aBLAs) for CT-P10 and CT-P6 to the FDA in April and May of last year, respectively. However, it received CRLs (complete

The trial showed a statistically significant and clinically meaningful improvement in progression-free survival (PFS) for patients treated with EPd compared with pomalidomide and dexamethasone (Pd) alone. ELOQUENT-3 is

However, the trial dubbed, Enforce, will be continued to study the drug’s performance in the treatment of episodic cluster headache as planned. Originally, the late-stage trial featured the

Top-line trial data were previously reported on 8 May 2018 and an update was provided on 11 May 2018. The biomarker data confirms that Traumakine treatment did not

Sage received Breakthrough Therapy Designation from the U.S. Food and Drug Administration (FDA) for SAGE-217 in MDD in February 2018, and recently announced an expedited development plan for

The trials, named GEMINI-1 and GEMINI-2, assessed the 2DR against a three-drug regimen of dolutegravir and two nucleoside reverse transcriptase inhibitors in HIV-1 patients with baseline viral loads

The acquisition of Sanofi’s manufacturing centre and business located in Holmes Chapel provides Recipharm with a solid platform to take further advantage of the growing respiratory drug market.

Roche chief medical officer and global product development head Sandra Horning said: “Today’s approval is an important advance for women newly diagnosed with this type of ovarian cancer.